• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

铜死亡相关基因在三阴性乳腺癌中的预后分析。

Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer.

机构信息

Department of Oncology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.

Department of General Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.

出版信息

Front Immunol. 2022 Aug 1;13:922780. doi: 10.3389/fimmu.2022.922780. eCollection 2022.

DOI:10.3389/fimmu.2022.922780
PMID:35979353
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9376234/
Abstract

BACKGROUND

Cuproptosis is a copper-dependent cell death mechanism that is associated with tumor progression, prognosis, and immune response. However, the potential role of cuproptosis-related genes (CRGs) in the tumor microenvironment (TME) of triple-negative breast cancer (TNBC) remains unclear.

PATIENTS AND METHODS

In total, 346 TNBC samples were collected from The Cancer Genome Atlas database and three Gene Expression Omnibus datasets, and were classified using R software packages. The relationships between the different subgroups and clinical pathological characteristics, immune infiltration characteristics, and mutation status of the TME were examined. Finally, a nomogram and calibration curve were constructed to predict patient survival probability to improve the clinical applicability of the CRG_score.

RESULTS

We identified two CRG clusters with immune cell infiltration characteristics highly consistent with those of the immune-inflamed and immune-desert clusters. Furthermore, we demonstrated that the gene signature can be used to evaluate tumor immune cell infiltration, clinical features, and prognostic status. Low CRG_scores were characterized by high tumor mutation burden and immune activation, good survival probability, and more immunoreactivity to CTLA4, while high CRG_scores were characterized by the activation of stromal pathways and immunosuppression.

CONCLUSION

This study revealed the potential effects of CRGs on the TME, clinicopathological features, and prognosis of TNBC. The CRGs were closely associated with the tumor immunity of TNBC and are a potential tool for predicting patient prognosis. Our data provide new directions for the development of novel drugs in the future.

摘要

背景

铜死亡是一种依赖铜的细胞死亡机制,与肿瘤进展、预后和免疫反应有关。然而,铜死亡相关基因(CRGs)在三阴性乳腺癌(TNBC)肿瘤微环境(TME)中的潜在作用尚不清楚。

患者和方法

从 The Cancer Genome Atlas 数据库和三个基因表达谱数据集共收集了 346 例 TNBC 样本,使用 R 软件包进行分类。检查了不同亚组与临床病理特征、免疫浸润特征和 TME 突变状态之间的关系。最后,构建了列线图和校准曲线来预测患者的生存概率,以提高 CRG_score 的临床适用性。

结果

我们确定了两个具有与免疫炎症和免疫荒漠聚类高度一致的免疫细胞浸润特征的 CRG 聚类。此外,我们表明该基因特征可用于评估肿瘤免疫细胞浸润、临床特征和预后状态。低 CRG_分数的特征是高肿瘤突变负担和免疫激活、良好的生存概率以及对 CTLA4 的更多免疫反应,而高 CRG_分数的特征是基质途径的激活和免疫抑制。

结论

本研究揭示了 CRGs 对 TNBC 的 TME、临床病理特征和预后的潜在影响。CRGs 与 TNBC 的肿瘤免疫密切相关,是预测患者预后的潜在工具。我们的数据为未来新型药物的开发提供了新的方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/ac1a57fa9db8/fimmu-13-922780-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/9124ab413021/fimmu-13-922780-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/8a88c03eb990/fimmu-13-922780-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/46a0c98a5b5d/fimmu-13-922780-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/af4c6d46401c/fimmu-13-922780-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/bc55fc71104b/fimmu-13-922780-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/993fb6a88e2c/fimmu-13-922780-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/9cf01bc9ead7/fimmu-13-922780-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/9cabe73ae7c2/fimmu-13-922780-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/e5186df5f76a/fimmu-13-922780-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/445fd0d99cd7/fimmu-13-922780-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/72c04387d4c2/fimmu-13-922780-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/ac1a57fa9db8/fimmu-13-922780-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/9124ab413021/fimmu-13-922780-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/8a88c03eb990/fimmu-13-922780-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/46a0c98a5b5d/fimmu-13-922780-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/af4c6d46401c/fimmu-13-922780-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/bc55fc71104b/fimmu-13-922780-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/993fb6a88e2c/fimmu-13-922780-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/9cf01bc9ead7/fimmu-13-922780-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/9cabe73ae7c2/fimmu-13-922780-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/e5186df5f76a/fimmu-13-922780-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/445fd0d99cd7/fimmu-13-922780-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/72c04387d4c2/fimmu-13-922780-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3395/9376234/ac1a57fa9db8/fimmu-13-922780-g012.jpg

相似文献

1
Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer.铜死亡相关基因在三阴性乳腺癌中的预后分析。
Front Immunol. 2022 Aug 1;13:922780. doi: 10.3389/fimmu.2022.922780. eCollection 2022.
2
Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.鉴定胃癌中与铜死亡相关的亚型,构建预后模型和肿瘤微环境景观。
Front Immunol. 2022 Nov 21;13:1056932. doi: 10.3389/fimmu.2022.1056932. eCollection 2022.
3
Comprehensive analysis of cuproptosis-related genes in immune infiltration and prognosis in lung adenocarcinoma.肺腺癌中铜死亡相关基因在免疫浸润和预后中的综合分析
Comput Biol Med. 2023 May;158:106831. doi: 10.1016/j.compbiomed.2023.106831. Epub 2023 Apr 5.
4
Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.鉴定新型铜死亡相关基因特征并对低级别脑胶质瘤患者进行综合分析。
Front Immunol. 2022 Aug 15;13:933973. doi: 10.3389/fimmu.2022.933973. eCollection 2022.
5
Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma.铜死亡相关风险评分预测结肠腺癌的预后并表征肿瘤微环境。
Front Oncol. 2023 Jun 2;13:1152681. doi: 10.3389/fonc.2023.1152681. eCollection 2023.
6
Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer.乳腺癌中铜死亡相关基因的综合分析及肿瘤微环境浸润特征分析。
Front Immunol. 2022 Oct 20;13:978909. doi: 10.3389/fimmu.2022.978909. eCollection 2022.
7
Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.铜死亡相关特征可预测肝细胞癌的预后、肿瘤微环境和药物敏感性。
J Immunol Res. 2022 Nov 16;2022:3393027. doi: 10.1155/2022/3393027. eCollection 2022.
8
Crosstalk of cuproptosis-related subtypes, establishment of a prognostic signature, and immune infiltration characteristics in gastric cancer.胃癌中铜死亡相关亚型的相互作用、预后特征的建立及免疫浸润特征
Heliyon. 2024 Jan 11;10(2):e24411. doi: 10.1016/j.heliyon.2024.e24411. eCollection 2024 Jan 30.
9
The therapeutic and prognostic role of cuproptosis-related genes in triple negative breast cancer.铜死亡相关基因在三阴性乳腺癌中的治疗和预后作用。
BMC Bioinformatics. 2023 May 31;24(1):223. doi: 10.1186/s12859-023-05348-3.
10
Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.铜死亡相关基因与肝细胞癌临床结局及肿瘤免疫微环境的关系。
Pathol Oncol Res. 2022 Sep 21;28:1610558. doi: 10.3389/pore.2022.1610558. eCollection 2022.

引用本文的文献

1
Systematic analysis identifies CDKN2A as a prognostic biomarker for hepatocellular carcinoma.系统分析确定CDKN2A为肝细胞癌的预后生物标志物。
Discov Oncol. 2025 Aug 30;16(1):1657. doi: 10.1007/s12672-025-03496-x.
2
Exploring Cuproptosis-Related Prognostic Signature for Hepatocellular Carcinoma: Bioinformatics and In Vitro Analyses.探索肝细胞癌的铜死亡相关预后特征:生物信息学与体外分析
Dig Dis Sci. 2025 Aug 28. doi: 10.1007/s10620-025-09354-8.
3
Advances in novel cell death mechanisms in breast cancer: intersecting perspectives on ferroptosis, cuproptosis, disulfidptosis, and pyroptosis.

本文引用的文献

1
Copper induces cell death by targeting lipoylated TCA cycle proteins.铜通过靶向脂酰化 TCA 循环蛋白诱导细胞死亡。
Science. 2022 Mar 18;375(6586):1254-1261. doi: 10.1126/science.abf0529. Epub 2022 Mar 17.
2
Tumor-B-cell interactions promote isotype switching to an immunosuppressive IgG4 antibody response through upregulation of IL-10 in triple negative breast cancers.肿瘤 B 细胞相互作用通过上调三阴性乳腺癌中的 IL-10 促进同种型转换为免疫抑制性 IgG4 抗体反应。
J Transl Med. 2022 Mar 7;20(1):112. doi: 10.1186/s12967-022-03319-5.
3
Copper-induced tumor cell death mechanisms and antitumor theragnostic applications of copper complexes.
乳腺癌新型细胞死亡机制的研究进展:铁死亡、铜死亡、二硫死亡和焦亡的交叉视角
Mol Cancer. 2025 Aug 27;24(1):224. doi: 10.1186/s12943-025-02445-0.
4
The interaction network between intestinal flora and cell death in microecosystem of pan-cancers.全癌微生态系统中肠道菌群与细胞死亡之间的相互作用网络。
Int J Med Sci. 2025 May 16;22(11):2596-2608. doi: 10.7150/ijms.111723. eCollection 2025.
5
Enhanced prognostic and immunomodulatory effects of novel cuproptosis-related long noncoding RNAs in wilms tumor.新型铜死亡相关长链非编码RNA在肾母细胞瘤中的增强预后和免疫调节作用
Front Mol Biosci. 2025 May 27;12:1566551. doi: 10.3389/fmolb.2025.1566551. eCollection 2025.
6
Targeting cuproptosis for cancer therapy: Focus on the anti-tumor immune system.针对铜死亡进行癌症治疗:聚焦抗肿瘤免疫系统。
Cancer Pathog Ther. 2024 Jul 27;3(3):226-243. doi: 10.1016/j.cpt.2024.07.005. eCollection 2025 May.
7
The molecular mechanism and therapeutic landscape of copper and cuproptosis in cancer.癌症中铜及铜死亡的分子机制与治疗前景
Signal Transduct Target Ther. 2025 May 9;10(1):149. doi: 10.1038/s41392-025-02192-0.
8
Construction of a novel five programmed cell death-related gene signature as a promising prognostic model for triple negative breast cancer.构建一种新型的五个程序性细胞死亡相关基因特征作为三阴性乳腺癌有前景的预后模型。
PeerJ. 2025 Apr 28;13:e19359. doi: 10.7717/peerj.19359. eCollection 2025.
9
Comprehensive analysis of prognosis and tumor immune microenvironment of cuproptosis-related gene CDKN2A in lung adenocarcinoma.肺腺癌中铜死亡相关基因CDKN2A的预后及肿瘤免疫微环境综合分析
BMC Pulm Med. 2025 Apr 14;25(1):179. doi: 10.1186/s12890-025-03631-y.
10
Unveiling the key mechanisms of FOLR2+ macrophage-mediated antitumor immunity in breast cancer using integrated single-cell RNA sequencing and bulk RNA sequencing.利用整合的单细胞RNA测序和批量RNA测序揭示FOLR2+巨噬细胞介导的乳腺癌抗肿瘤免疫的关键机制。
Breast Cancer Res. 2025 Mar 5;27(1):31. doi: 10.1186/s13058-025-01980-4.
铜诱导的肿瘤细胞死亡机制及铜配合物的抗肿瘤诊断与治疗应用。
Nanomedicine (Lond). 2022 Feb;17(5):303-324. doi: 10.2217/nnm-2021-0374. Epub 2022 Jan 21.
4
Regulatory T cells: Their role in triple-negative breast cancer progression and metastasis.调节性 T 细胞:其在三阴性乳腺癌进展和转移中的作用。
Cancer. 2022 Mar 15;128(6):1171-1183. doi: 10.1002/cncr.34084. Epub 2022 Jan 6.
5
Establishment and Validation of Prognostic Nomograms Based on Serum Copper Level for Patients With Early-Stage Triple-Negative Breast Cancer.基于血清铜水平的早期三阴性乳腺癌患者预后列线图的建立与验证
Front Cell Dev Biol. 2021 Nov 25;9:770115. doi: 10.3389/fcell.2021.770115. eCollection 2021.
6
Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.三阴性乳腺癌的治疗现状——选择增多,需求变化。
Nat Rev Clin Oncol. 2022 Feb;19(2):91-113. doi: 10.1038/s41571-021-00565-2. Epub 2021 Nov 9.
7
Copper in tumors and the use of copper-based compounds in cancer treatment.肿瘤中的铜与癌症治疗中铜基化合物的应用。
J Inorg Biochem. 2022 Jan;226:111634. doi: 10.1016/j.jinorgbio.2021.111634. Epub 2021 Oct 19.
8
Clinical and therapeutic relevance of cancer-associated fibroblasts.癌症相关成纤维细胞的临床和治疗相关性。
Nat Rev Clin Oncol. 2021 Dec;18(12):792-804. doi: 10.1038/s41571-021-00546-5. Epub 2021 Sep 6.
9
Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells.B 细胞通过髓系来源抑制细胞影响三阴性乳腺癌的免疫检查点阻断。
Commun Biol. 2021 Jul 12;4(1):859. doi: 10.1038/s42003-021-02375-9.
10
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.IMpassion131 研究是一项双盲、安慰剂对照、随机 III 期临床试验,旨在评估一线紫杉醇联合或不联合阿替利珠单抗治疗不可切除局部晚期/转移性三阴性乳腺癌的主要结果。
Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1.